Amylin Rejected $3.5 billion Bid from Bristol-Myers Squibb
Bloomberg reported this morning that Bristol-Squibb Myers (NYSE: BMY) approached Amylin (NASDSAQ: AMLN) with a $3.5 billion offer or $22 per share. The headlines indicate that the bid was rejected and...







